Among patients with baseline measurable disease, overall response rates were 71% (95% CI: 48–89) in patients with treatment-naive RET-mutant MTC and 60% (95% CI: 46–73) in patients who had previously received cabozantinib or vandetanib, or both, and 89% (95% CI: 52–100) in patients with RET fusion–positive thyroid cancer [7]. The gene discussed is RET; the disease is thyroid cancer.